Personalized medicine in diabetes: Unraveling the disease casualty of HNF1A and HNF4A gene coding variants of “unknown clinical significance” in two large Norwegian diabetes registries
- Prosjektnummer
- 912019
- Ansvarlig person
- Alba Kaci
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Doktorgradsstipend
- Helsekategori
- Metabolic and Endocrine
- Forskningsaktivitet
- 4. Detection and Diagnosis, 6. Treatment Evaluation
We have established a reference group for the research planning and implementation monitoring at the KG Jebsen Diabetes Center. This reference group consists of both a scientific advisory board (Prof. Leif Groop, Lund University; Prof. Peter Arner, Karolinska Institute; Prof. Karen Temple, University of Southampton) and research end-users including a member from the Norwegian Diabetes Association. The end- users are invited to provide talks and to participate at our KG Jebsen meetings every 6 months, the next meeting being September 24, 2015. The users are also our patients, that most likely will have improved diagnosies and targeted treatment as benefits.
The E3 SUMO ligase PIASγ is a novel interaction partner regulating the activity of diabetes associated hepatocyte nuclear factor-1α.
Sci Rep 2018 Aug 24;8(1):12780. Epub 2018 aug 24
PMID: 30143652 - Inngår i doktorgradsavhandlingen
Precision medicine in MODY-diabetes: Unraveling the disease causality of gene variants and new regulatory mechanisms
- Disputert:
- oktober 2019
- Hovedveileder:
- Ingvild Aukrust
- Alba Kaci Ph.d.-kandidat
- Pål Rasmus Njølstad Medveileder
- Lise Bjørkhaug Medveileder
- Ingvild Aukrust Hovedveileder
- Lise Bj. Gundersen Medveileder
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest